-
30 June 2025 13:46:34
- Source: Sharecast
30 June 2025
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Result of AGM
Cizzle Biotechnology, the UK based diagnostics developer, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a show of hands and were passed.
The proxy votes cast in respect of the resolutions were as follows:
|
Resolution |
For* |
Against |
Votes withheld |
||
|
Total votes |
% |
Total votes |
% |
|
|
|
1. To receive the Company's annual report and accounts for the year ended 31 December 2024 |
113,796,829 |
100.00 |
0 |
0.00 |
0 |
|
2. To approve the Directors' Remuneration Policy |
113,434,973 |
99.68 |
359,286 |
0.32 |
2,570 |
|
3. To approve the 2024 Remuneration Report |
113,529,139 |
99.77 |
265,120 |
0.23 |
2,570 |
|
4. To re-appoint Edwin Matthew Bower as a Director of the Company |
113,762,519 |
99.97 |
34,200 |
0.03 |
110 |
|
5. To re-appoint Allan John Syms as a Director of the Company |
113,762,519 |
100.00 |
0 |
0.00 |
34,310 |
|
6. To re-appoint PKF Littlejohn LLP as auditor of the Company |
113,696,829 |
99.91 |
100,000 |
0.09 |
0 |
|
7. To authorise the Directors to determine the auditor's remuneration |
113,796,709 |
100.00 |
110 |
0.00 |
10 |
|
8. Authorises the Directors to allot shares in the Company or to grant rights to subscribe for, or to convert any security into, shares in the Company |
113,796,719 |
100.00 |
110 |
0.00 |
0 |
|
9. Authorise the Directors to allot equity securities disapplying pre-emption rights |
112,297,509 |
98.68 |
1,499,310 |
1.32 |
10 |
|
10. That General Meetings may be called on not less than 14 days' notice |
113,796,829 |
100.00 |
0 |
0.00 |
0 |
Notes:
*"Votes For" include votes giving the Chairman's discretion.
Enquiries:
|
Cizzle Biotechnology Holdings plc |
Via IFC Advisory |
|
Allan Syms (Executive Chairman) |
|
|
Allenby Capital Limited |
+44(0) 20 3328 5656 |
|
John Depasquale / Piers Shimwell (Corporate Finance) |
|
|
Amrit Nahal (Sales and Corporate Broking) |
|
|
IFC Advisory Limited |
+44(0) 20 3934 6630 |
|
|
Tim Metcalfe |
|
|
|
Florence Staton |
|
|
About Cizzle Biotechnology
Based on the pioneering work of Professor Coverley and colleagues, on a naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B biomarker is highly associated with the presence of early-stage cancer. The company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.